For men whose prostate cancer returns after surgery, finding where it has spread is the decisive factor in whether treatment can remain curative. A new prospective head-to-head imaging trial challenges the dominance of the current gold-standard PSMA-PET tracer by demonstrating that a longer-lived copper-based alternative identifies substantially more disease at the earliest, most treatable stage of recurrence.
The trial enrolled 50 patients with biochemical recurrence following radical prostatectomy, defined by PSA values in the difficult 0.2–0.75 ng/ml range where conventional imaging routinely fails. Each participant underwent both 64Cu-SAR-bisPSMA PET/CT — imaged at 1 and 24 hours post-injection — and the established 68Ga-PSMA-11 PET/CT within a three-week window. The mean per-participant lesion count was 1.26 with the copper agent versus 0.48 with gallium, a 2.63-fold ratio (95% CI: 1.64–4.20, p < 0.0001). At the individual patient level, 78% of participants showed a clinically meaningful difference in detected lesions, with management plans altered accordingly after the copper scan results.
The performance advantage here is mechanistically grounded, not incidental. 64Cu carries a 12.7-hour physical half-life versus gallium-68's 68 minutes, enabling delayed 24-hour imaging when background tissue clearance is maximal and target-to-noise ratios are highest. The bivalent peptide design further increases PSMA receptor binding avidity. This mirrors lessons from 18F-based PSMA tracers, which also exploit longer half-lives for superior low-PSA detection. What distinguishes this study is the prospective, within-patient crossover design with a structured reference standard — considerably more rigorous than retrospective comparisons. Limitations include the modest 50-patient cohort, single-center enrollment, and absence of long-term survival or treatment-outcome data. Still, given the documented clinical impact on management decisions and the mechanistic rationale, this finding warrants attention as potentially practice-shaping for urologists and radiation oncologists managing early biochemical recurrence.